Literature DB >> 12113327

Epinephrine treatment of hypotension in very low birthweight infants.

M Heckmann1, A Trotter, F Pohlandt, W Lindner.   

Abstract

UNLABELLED: The aim of this study was to examine the influence of a continuous infusion of epinephrine (adrenaline) on mean arterial blood pressure (MABP), heart rate, urine output and base deficit in very low birthweight infants (VLBWI) with systemic hypotension. In VLBWI who received an infusion of epinephrine for at least 12 h the mean urine output, administered fluid volume, base deficit and administered buffer 12 h before and 12 h during the infusion were recorded. If the infusion was shorter, but given for at least 2 h, the mean heart rate and MABP 2 h before and 2 h during the infusion were recorded. Thirty-one infants with a gestational age of 26 (23-30) wk [median (minimum-maximum)] and birthweight 690 (390-1310) g were included in this retrospective chart review. The patients received an infusion of epinephrine at a postnatal age of 3 (1-21) d. The doses ranged between 0.05 and 2.6 microg kg(-1) per minute within the first 24 h of administration. Three of 31 infants received epinephrine on 2 different occasions. The MABP [+7 (-1 to 13) mmHg, p=0.000001] and the heart rate [+10 (-10 to 42) bpm, p=0.000036] increased significantly (n = 34), whereas total volume administration and urine output remained the same between the 2 periods (Wilcoxon matched pairs test). The base deficit increased significantly [-3 (-10.2 to 2.6), p = 0.0014, n = 19] without a change in the administration of buffer.
CONCLUSION: The infusion of epinephrine increased the MABP and the heart rate without decreasing urine output in VLBWI with hypotension not responding to a dopamine infusion up to 15 microg kg(-1) per minute. A potential adverse effect was an increase in metabolic acidosis.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12113327     DOI: 10.1080/080352502753711704

Source DB:  PubMed          Journal:  Acta Paediatr        ISSN: 0803-5253            Impact factor:   2.299


  5 in total

Review 1.  Which inotrope for which baby?

Authors:  N Evans
Journal:  Arch Dis Child Fetal Neonatal Ed       Date:  2006-05       Impact factor: 5.747

2.  Noradrenaline in preterm infants with cardiovascular compromise.

Authors:  Kirsten Rowcliff; Koert de Waal; Abdel-Latif Mohamed; Tejasvi Chaudhari
Journal:  Eur J Pediatr       Date:  2016-10-15       Impact factor: 3.183

3.  Optimal body temperature in transitional extremely low birth weight infants using heart rate and temperature as indicators.

Authors:  Robin B Knobel; Diane Holditch-Davis; Todd A Schwartz
Journal:  J Obstet Gynecol Neonatal Nurs       Date:  2010 Jan-Feb

4.  Clinical practice parameters for hemodynamic support of pediatric and neonatal septic shock: 2007 update from the American College of Critical Care Medicine.

Authors:  Joe Brierley; Joseph A Carcillo; Karen Choong; Tim Cornell; Allan Decaen; Andreas Deymann; Allan Doctor; Alan Davis; John Duff; Marc-Andre Dugas; Alan Duncan; Barry Evans; Jonathan Feldman; Kathryn Felmet; Gene Fisher; Lorry Frankel; Howard Jeffries; Bruce Greenwald; Juan Gutierrez; Mark Hall; Yong Y Han; James Hanson; Jan Hazelzet; Lynn Hernan; Jane Kiff; Niranjan Kissoon; Alexander Kon; Jose Irazuzta; Jose Irazusta; John Lin; Angie Lorts; Michelle Mariscalco; Renuka Mehta; Simon Nadel; Trung Nguyen; Carol Nicholson; Mark Peters; Regina Okhuysen-Cawley; Tom Poulton; Monica Relves; Agustin Rodriguez; Ranna Rozenfeld; Eduardo Schnitzler; Tom Shanley; Saraswati Kache; Sara Skache; Peter Skippen; Adalberto Torres; Bettina von Dessauer; Jacki Weingarten; Timothy Yeh; Arno Zaritsky; Bonnie Stojadinovic; Jerry Zimmerman; Aaron Zuckerberg
Journal:  Crit Care Med       Date:  2009-02       Impact factor: 7.598

5.  A comparison of combination dopamine and epinephrine treatment with high-dose dopamine alone in asphyxiated newborn piglets after resuscitation.

Authors:  Namdar Manouchehri; David L Bigam; Thomas Churchill; David Rayner; Chloe Joynt; Po-Yin Cheung
Journal:  Pediatr Res       Date:  2013-01-23       Impact factor: 3.756

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.